GBT Global Blood Therapeutics, Inc.

-0.10  -0%
Previous Close 29.20
Open 29.45
Price To book 4.15
Market Cap 1.27B
Shares 43,613,000
Volume 518,217
Short Ratio 1.57
Av. Daily Volume 1,300,850

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a initiated November 2016.
Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest
Announced January 18, 2017 that Phase 3 enrollment has commenced. Previous guidance is for top-line data due 1H 2019.
Sickle cell disease in adults
Phase 2a initiated June 2016. Data due 2017
Idiopathic pulmonary fibrosis (IPF)
Phase 2a initiated June 2016. Preliminary data due at European Hematology Association (EHA) - June 24, 2017.
Sickle cell disease in adolescents

Latest News

  1. Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Association’s 22nd Congress
  2. Global Blood reports 1Q loss
  3. Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results
  4. 5 Top Performing Stocks of the Best ETF of Q1
  5. Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference
  6. Market Is Home on the Range Again
  7. Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion
  8. 5 Stocks The Best Performing Hedge Funds Are Piling Into
  9. Global Blood Therapeutics Demonstrates 'Compelling Potential' In Sickle Cell Treatment
  10. Market Takes 'National Napping Day' Seriously
  11. Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results
  12. Biotech Leads the Way Again Today
  13. These 3 Stocks Have Doubled Investors' Money
  14. Late Market Rally but No Bounce for Bulls
  15. Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease
  16. Here’s Our Take On The Global Blood Therapeutics Inc (GBT) Rumors
  17. Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning
  18. Novo Nordisk in Talks to Buy Global Blood Therapeutics (NVO,GBT)
  19. Market Set Up for Oversold Bounce